Erschienen in:
23.08.2022 | ASO Research Letter
Transgender and Non-binary Persons in Contemporary Oncology Randomized Clinical Trials
verfasst von:
Enrique O. Martinez, BS, Micah Rubin, BA, Tessa Miller, MPH, Chandler S. Cortina, MD, MS, FSSO, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2022
Einloggen, um Zugang zu erhalten
Excerpt
An increasing number of individuals in the United States identify as transgender or non-binary (TGNB), defined as a person who’s gender is different from their sex assigned at birth or an individual who does not identify within the male/female gender dichotomy.
1 The stigmatization of TGNB individuals has led to significant healthcare disparities in oncologic care.
2, 3 There is a paucity of data surrounding oncologic risks, screening, and cancer care for persons on gender-affirming hormone therapy (GAHT), after gender-affirming procedures, or how the physiologic and psychosocial changes from gender-affirming therapies may alter response to cancer treatment.
2, 3 Current research aims to elucidate the potential long-term effects of gender-affirming care, especially in the biological development of hormonally sensitive malignancies such as breast, prostate, and gynecological cancers.
4, 5 …